Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma

31 July 2020: Clinical Research

Ying Yang ^AEF , Zhuogang Liu ^ABC , Hongtao Wang ^ACEG*

DOI: 10.12659/MSM.923716

Med Sci Monit 2020; 26:e923716

Table 2 Univariate analysis of the influence of clinical parameters on OS in MM patients (P<0.05).

Characteristics		n	OS, %	P-value
Sex	Male	67	62.7	0.805
Sex	Female	35	65.7	0.805
Age, y		49	71.4	0.083
Age, y	≥60	53	56.6	0.083
BMI, kg/m		42	66.7	0.335
BMI, kg/m	≥22.85	44	75.0	0.335
DS staging	Stage I	7	85.7	0.138
	Stage II	15	66.7
	Stage III	80	61.3
	Group A	74	67.6	0.054
	Group B	28	53.6	0.054
ISS staging	Stage I	5	100	0.088
	Stage II	36	71.9
	Stage III	61	60.7
ISS dichotomy	Early stage	41	75.7	0.04
ISS dichotomy	Late stage	61	60.7	0.04
L-ISS staging	Stage I	5	80	0.004
	Stage II	56	75
	Stage III	41	46.3
L-ISS dichotomy	Early stage	61	78
L-ISS dichotomy	Late stage	41	48.7
M-fraction type	IgG	49	75.5	0.004
	IgA	20	65
	Light chain	26	46.2
Light chain type	κ	55	60	0.519
Light chain type	λ	43	72.1	0.519
ALC		51	52.9	0.045
ALC	≥1.43×10/L	51	74.5	0.045
AMC		52	67.3	0.284
AMC	≥0.4×10/L	50	60.0	0.284
LMR		50	50.0
LMR	≥3.7	52	76.9
HGB, g/L		71	60.6	0.142
HGB, g/L	≥100	31	71.0	0.142
PLT		36	61.1	0.381
PLT	≥135×10/L	66	65.2	0.381
LDH, U/L		60	58.3	0.914
LDH, U/L	≥243	42	60.0	0.914
β2-MG dichotomy, mg/L		36	77.8	0.053
β2-MG dichotomy, mg/L	≥5.5	61	60.7	0.053
ALB, g/L		64	69.8	0.039
ALB, g/L	≥35	38	55.3	0.039
Ca, mmol/L		90	64.4	0.545
Ca, mmol/L	≥2.75	12	58.3	0.545
IgG dichotomy, g/L		31	80.6	0.362
IgG dichotomy, g/L	≥70	16	68.8	0.362
IgA dichotomy, g/L		13	76.9	0.109
IgA dichotomy, g/L	≥50	7	42.9	0.109